Interested in this late-breaker, comparative study of secukinumab (IL17) vs adalimumab (TNF) in AxSpa No difference in radiographic progression at 1 year - in line with my perception of relative equality for these treatments Need long term data! #ACR22 @rheumnow abstr#L15 https://t.co/7EdhJsW3bq